Additional file 1: Figure S1-4. of Case report: mechanisms of HIV elite control in two African women

Figure S1. T cell activation in the CAPRISA cohorts. CD4+ and CD8+ T cell activation, as measured by the frequency of HLA-DR-positive cells. Figure S2. Flow cytometry plots of HIV-specific CD4+ responses in elite controller 2 pre- and post-infection. Figure S3. HIV neutralizing antibody responses in elite controllers. Figure S4. Host genetic factor expression in the CAPRISA cohorts. (PDF 634 kb

Comparison of FGS+ and FGS−.

<p>Figures comparing the FGS positive (genital sandy patches) and negative (no genital sandy patches, negative <i>Schistosoma</i> PCR in cervicovaginal lavage/urine and negative urine microscopy for ova). Figures show blood (A–B) and cervical samples (C–D).</p

Gating strategy.

<p>Figures showing the gating strategy for A) CD3⁺ B) CD3⁻CD56⁺ C) CD3⁺CD4⁺ and CD3⁺CD8⁺ and D) CD3⁻CD56⁻CD14⁺.</p

Flowchart.

<p>Flowchart showing the inclusion of study participants (FGS =  female genital schistosomiasis, CVL =  cervicovaginal lavage).</p

Characteristics of study participants by female genital schistosomiasis (FGS) status.

a<p>Analysis done on all if not stated otherwise.</p>b<p>Pearson’s chi-square or Fisher’s exact test.</p>c<p>Mann-Whitney U test.</p>d<p>Not compared due to inclusion criteria of the negative group.</p>e<p>The pathology in female genital schistosomiasis is also due to dead, calcified ova. PCR may therefore be negative.</p

Effect of praziquantel treatment.

<p>Figures comparing FGS positive individuals in blood (A–B) and cervical samples (C–D) before and after praziquantel (40 mg/kg) treatment.</p

Colposcopic image of cervix with female genital schistosomiasis.

<p>The image shows sandy patches appearing as grains (arrows point to some examples) and contact bleeding.</p